Hot Biotech Stocks: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD)

Technology Stocks News 13

Investment analysts at JPMorgan Chase & Co. dropped their target price on shares of VIVUS (NASDAQ:VVUS) from $8.00 to $5.00 in a note issued to investors on Tuesday, Stock Ratings Network reports. JPMorgan Chase & Co.’s price target would indicate a potential downside of 10.15% from the company’s current price. VIVUS, Inc. (NASDAQ:VVUS)stock performance was 7.23% in last session and finished the day at $ 5.5650. Traded volume was 10,887,712 shares in the last session and the average volume of the stock remained 3,606,540 shares. The beta of the stock remained 1.53. VIVUS, Inc. (NASDAQ:VVUS) insider ownership is 0.10%.

Arena Pharmaceuticals (NASDAQ:ARNA)’s shares have received a consensus recommendation of “Hold” from the nine analysts that are presently covering the stock, Stock Ratings Network reports. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)dropped 0.44% to $ 6.85 yesterday on volume of 8,441,293 shares. The intra-day range of the stock was $ 6.85 – 7.15. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)has a market capitalization of $ 1.50 billion.

Ariad Pharmaceuticals (NASDAQ:ARIA) announced its earnings results on Wednesday. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.05, StockRatingsNetwork reports. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s stock on May 6, 2014 reported a decrease of – 7.08% to the closing price of $ 7.09. Its fifty two weeks range is $ 2.15 – 23.00. The total market capitalization recorded $ 1.32 billion. The overall volume in the last trading session was 11,456,305 shares. In its share capital, Ariad Pharmaceuticals, Inc.(NASDAQ:ARIA) has 186.80 million outstanding shares.

Gilead Sciences (NASDAQ:GILD) CFO Robin L. Washington unloaded 27,600 shares of Gilead Sciences stock on the open market in a transaction dated Thursday, May 1st. The shares were sold at an average price of $79.16, for a total value of $2,184,816.00.On Friday, shares of Gilead Sciences, Inc. (NASDAQ:GILD) dropped 1.89% to close the day at $ 78.32. Company return on investment (ROI) is 18.70% and its monthly performance is recorded as 8.48% .Gilead Sciences, Inc. (NASDAQ:GILD) quarterly revenue growth is -4.51%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone